Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$27.52
+0.02 (+0.07%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-127.1M · quality 71.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
19/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.6B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-10.7%
↓Gross Margin
42.6%
↓Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-7.7%
FCF CAGR
—
FCF margin
-23.5%
FCF / Net income
0.55x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $541.4M · net income $-231.3M · FCF $-127.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $541.4M | $541.4M | $649.0M | $602.3M | $688.6M |
| Net Income | $-231.3M | $-231.3M | $-69.3M | $-120.8M | $-14.0M |
| EBITDA | $-140.0M | $-140.0M | $14.4M | $-78.5M | $46.8M |
| EPS | -1.77 | -1.77 | -0.53 | -0.93 | -0.11 |
| Gross Margin | 42.6% | 42.6% | 42.8% | 42.7% | 48.5% |
| Operating Margin | -22.5% | -22.5% | -10.5% | -17.7% | -0.7% |
| Net Margin | -42.7% | -42.7% | -10.7% | -20.1% | -2.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.02 | 0.03 | 0.04 |
| Current Ratio | 4.17 | 4.17 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-127.1M | $-127.1M | $-20.4M | $-162.1M | $-120.9M |
| Returns | |||||
| ROE | -10.7% | -10.7% | -2.9% | -4.9% | -0.6% |
| Valuation | |||||
| EV/EBITDA | — | — | 179.11 | — | 87.29 |
| P/B | 1.66 | 1.66 | 1.24 | 1.75 | 2.05 |
| Growth & Yield | |||||
| Revenue Growth | -16.6% | -16.6% | 7.8% | -12.5% | — |
| EPS Growth | -234.0% | -234.0% | 43.0% | -745.5% | — |
| Dividend Yield | 0.4% | 0.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+17.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.53 → -1.77
Residual
+17.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.